Summary
. Short-term (90 day) age adjusted survival of incident RRT patients in the 2015 cohort was similar to the 2014 cohort (96.5% versus 96.8%). . One year after 90 day age adjusted survival for incident RRT patients in the 2015 cohort fell slightly to 90.0% compared with the previous year (90.2%). . There was a difference in one year after 90 day incident survival by age group and diagnosis of diabetes: patients with diabetes aged ,65 years had worse one year after 90 day survival than patients without diabetes, but for older patients with diabetes (565 years) survival was similar compared to those patients without diabetes.
. One year age adjusted survival for prevalent dialysis patients was similar at 88.0% in the 2015 cohort, compared with 88.3% in the 2014 cohort. Age adjusted one year survival for prevalent dialysis patients with diabetic primary renal disease has been declining slightly from 2012 onwards. . Centre and UK country variability was evident in incident and prevalent patient survival after adjusting to age 60. Further adjustment for comorbidity was not possible due to missing data. . The relative one year risk of death for prevalent RRT patients compared with the general population was approximately 21 for age group 35-39 years compared with 1.5 at age 85+ years, but the relative risk of death for younger patients has improved over time. . In the prevalent RRT population, cardiovascular disease was the most common cause of death and accounted for 24% of deaths, with infection accounting for 20%. Treatment withdrawal accounted for 17% of deaths and has increased in recent years from historical levels.
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Introduction
The analyses presented in this chapter examine a) survival from the start of renal replacement therapy (RRT) of adult patients; b) survival amongst prevalent adult dialysis patients alive on 31 December 2015; c) the death rate in the UK compared to the general population; d) the cause of death for incident and prevalent adult patients. They encompass the outcomes of the total incident adult UK RRT population (2015) reported to the UK Renal Registry (UKRR), including the 19% who started on peritoneal dialysis (PD) and the 8% who received a pre-emptive renal transplant. These results are therefore a true reflection of the outcomes in the whole UK adult incident RRT population. Analyses of survival within the first year of starting RRT include patients who were recorded as having started RRT for established renal failure (as opposed to acute kidney injury) but who had died within the first 90 days of starting RRT, a group excluded from most other countries' registry data. As is common in other countries, survival analyses are also presented for the first year after 90 days.
The term established renal failure (ERF) used throughout this chapter is synonymous with the terms end stage renal failure (ESRF) and end stage renal disease (ESRD), which are in more widespread international usage. Within the UK, patients have disliked the term 'end stage'; the term ERF was endorsed by the English National Service Framework for Renal Services, published in 2004.
Since 2006, the UKRR has openly reported and published centre attributable RRT survival data. These are raw data that must be interpreted with caution. The UKRR adjusts for the different age distributions of patients in different centres, but lacks sufficient data from many participating centres to allow adjustment for primary renal diagnosis, other comorbidities at start of RRT (comorbidity, especially diabetes, is a major factor associated with survival [1] [2] [3] ) and ethnic origin, which have been shown to have an impact on outcome (for instance, better survival is expected in centres with a higher proportion of Black and South Asian patients) [4] . This lack of data on the centre level case-mix makes interpretation of any apparent difference in survival between centres and UK countries difficult. Despite the uncertainty about apparent differences in outcome, any centre which appears to be an outlier will be subject to the UKRR clinical governance procedures as set out in chapter 2 of the 2009 UKRR Annual Report [5] .
Methods
The unadjusted survival probabilities (with 95% confidence intervals) were calculated using the Kaplan-Meier method, in which the probability of surviving more than a given time can be estimated for all members of a cohort of patients overall or by subgroup such as age group, but without any adjustment for confounding factors such as age that affect the chances of survival. Where centres are small, or the survival probabilities are greater than 90%, the confidence intervals are only approximate.
In order to estimate the difference in survival of different subgroups of patients within the cohort, a stratified proportional hazards model (Cox) was used where appropriate. The results from the Cox model were interpreted using a hazard ratio. When comparing two groups, the hazard ratio is the ratio of the estimated hazard for group A relative to group B, where the hazard is the risk of dying at time t given that the individual has survived until this time. The underlying assumption of a proportional hazards model is that the hazard ratio remains constant throughout the period under consideration. Whenever used, the assumptions of the proportional hazards model were tested by plotting the log(−log(survival)) versus the log of survival time or by testing time dependent covariates in the model.
To allow for comparisons between centres with differing age distributions, survival analyses were adjusted for age and reported as survival adjusted to age 60. This gives an estimate of what the survival would have been if all patients in that centre had been aged 60 at the start of RRT. This age was chosen because it was approximately the average age of patients starting RRT 17 years ago at the start of the UKRR's data collection. The average age of patients commencing RRT in the UK has recently stabilised around an age of 62 years, but the UKRR has maintained age adjustment to 60 years for comparability with all previous years' analyses. Diabetic patients were included in all analyses unless stated otherwise and for some analyses, diabetic and non-diabetic patients were analysed separately and compared. Non-diabetic patients were defined as all patients excluding those patients with diabetes as the primary renal disease.
Centre variability for incident and prevalent patient survival was analysed using a funnel plot. For any number of patients in the incident or prevalent cohort (x-axis), one can identify whether any given survival probability (y-axis) falls within, plus or minus two standard deviations (SDs) from the national mean (solid lines, 95% limits) or three SDs (dotted lines, 99.9% limits). All analyses were undertaken using SAS 9.3.
Cambridge renal centre (Addenbrooke's) was unable to submit 2015 or 2016 data at patient level prior to the UKRR closing the database and only provided summary numbers of patients starting RRT by treatment modality. This centre is therefore excluded from analyses in this chapter for 2015 and 2016.
Definition of RRT start date
The incident survival figures quoted in this chapter are from the first day of RRT whether with dialysis or a pre-emptive transplant. In the UKRR all patients starting RRT for ERF are included from the date of the first RRT treatment wherever it took place (a date currently defined by the clinician) if the clinician considered the renal failure irreversible. Should a patient recover renal function within 90 days they were then excluded. These UK data therefore may include some patients who died within 90 days who had developed acute, potentially reversible renal failure but were recorded by the clinician as being in irreversible ERF.
Previously, the UKRR asked clinicians to re-enter a code for ERF in patients initially coded as having acute renal failure once it had become clear that there was no recovery of kidney function. However, adherence to this requirement was very variable, with some clinicians entering a code for ERF only once a decision had been made to plan for long-term RRT [6] . All UK nephrologists have now been asked to record the date of the first haemodialysis (HD) session and to record whether the patient was considered to have acute kidney injury (acute renal failure) or to be in ERF at the time. For patients initially categorised as 'acute', but who were subsequently categorised as ERF, the UKRR assigns the date of this first 'acute' session as the date of start of RRT.
UKRR analyses of electronic data extracted for the month immediately prior to the start date of RRT provided by clinicians highlighted additional inconsistencies in the definition of this first date when patients started on PD, with the date of start reported to the UKRR being later than the actual date of start. These findings are described in detail in chapter 13 of the 2009 Annual Report [6] . This concern is unlikely to be unique to the UK, but will be common to analyses from all renal centres and registries.
In addition to these problems of defining day 0 within one country, there is international variability when patient data are collected by national registries with some countries (often for financial re-imbursement or administrative reasons) defining the 90th day after starting RRT as day 0, whilst others collect data only on those who have survived 90 days and report as zero the number of patients dying within the first 90 days.
Thus, as many other national registries do not include reports on patients who do not survive the first 90 days, survival from 90 days onwards is also reported to allow international comparisons. This distinction is important, as there is a much higher death rate in the first 90 days, which would distort comparisons.
Methodology for incident patient survival
The incident population is defined as all patients over 18 who started RRT at UK renal centres. Patients were considered 'incident' at the time of their first RRT, thus patients re-starting dialysis after a failed transplant were not included in the incident RRT cohort (see appendix B:1 for a detailed definition of the incident (take-on) population).
For incident survival analyses, patients newly transferred into a centre who were already on RRT were excluded from the incident population for that centre and were counted at the centre at which they started RRT. Some patients recovered renal function after more than 90 days but subsequently returned to RRT and for these patients the most recent start of RRT was used.
The incident survival cohort was NOT censored at the time of transplantation and therefore included the survival of the 8% who received a pre-emptive transplant. An additional reason for not censoring was to facilitate comparison between centres. Centres with a high proportion of patients of South Asian and Black origin are likely to have a healthier dialysis population, because South Asian and Black patients are less likely to undergo early transplantation [7] and centres with a high pre-emptive transplant rate are likely to have a less healthy dialysis population as transplantation selectively removes fitter patients. However, censoring at transplantation was performed in the 1997-2015 cohort to establish the effect on long term survival by age group and also in the 2012-2015 cohort to investigate the effect on the outlying status of centres.
The one year incident survival is for patients who started RRT from 1 October 2014 until the 30 September 2015 and followed up for one full year (e.g. patients starting RRT on 1 December 2014 were followed through to 30 November 2015). The 2016 incident patients could not be analysed as they had not yet been followed for a sufficient length of time. For analysis of one year after 90 day survival, patients who started RRT from 1 October 2014 until 30 September 2015 were included in the cohort and they were followed up for a full year after the first 90 days of RRT.
Two years incident data (2014-2015) were combined to increase the size of the patient cohort, so that any differences between the four UK countries could be more reliably identified. To help identify any centre differences in survival from the small centres (where confidence intervals are large), an analysis of one year after 90 day survival using a rolling four year combined incident RRT cohort from 2012 to 2015 was also undertaken. A 10 year rolling cohort was used when analysing trends over time and for long term survival, a cohort from 1997 to 2015 was analysed.
The death rate per 1,000 patient years was calculated by dividing the number of deaths by the person years exposed. Person years exposed are the total years at risk for each patient (until death, recovery or lost to follow up). The death rate is presented by age group and UK nation.
Adjustment of one year after 90 day survival for the effect of comorbidity was undertaken using a rolling four year combined incident RRT cohort from 2012 to 2015. Twenty-nine centres returned 585% of comorbidity data for patients in the combined cohort. Adjustment was first performed to a mean age of 60 years, then to the average distribution of primary diagnoses for the 29 centres. The individual centre data were then further adjusted for average distribution of comorbidity present at these centres.
Methodology for prevalent dialysis patient survival
The prevalent dialysis patient group was defined as all patients over 18 years old, alive and receiving dialysis on 31 December 2015 who had been on dialysis for at least 90 days at one of the UK adult renal centres. Prevalent dialysis patients on 31 December 2015 were followed-up in 2016 and were censored at transplantation. When a patient is censored at transplantation, this means that the patient is considered as alive up to the point of transplantation, but the patient's status post-transplant is not considered.
As discussed in previous reports, comparison of survival of prevalent dialysis patients between centres is complex. Survival of prevalent dialysis patients can be studied with or without censoring at transplantation and it is common practice in some registries to censor at transplantation. Censoring could cause apparent differences in survival between those renal centres with a high transplant rate and those with a low transplant rate, especially in younger patients where the transplant rate is highest. Censoring at transplantation systematically removes younger fitter patients from the survival data. The differences are likely to be small due to the relatively small proportion of patients being transplanted in a given year compared to the whole dialysis population (about 14% of the dialysis population aged under 65 and about 2% of the population aged 65 years and over). To allow comparisons with other registries the survival results for prevalent dialysis patients CENSORED for transplantation have been quoted. To
Survival in UK RRT patients in 2016
Nephron 2018;139(suppl1):117-150 understand survival of patients, including survival following transplantation, the incident patient analyses should be viewed. The effect of not censoring at transplantation was performed in the 2015 cohort to investigate the effect on the outlying status of centres.
Methodology for comparing mortality in prevalent RRT patients with mortality in the general population Data on the UK population in mid-2016 and the number of deaths in each age group in 2016 were obtained from the Office of National Statistics [8] . The age specific UK death rate was calculated as the number of deaths in the UK per thousand people in the population. The age specific expected number of deaths in the RRT population was calculated by applying the UK age specific death rate to the total of years exposed for RRT patients in that age group. This is expressed as deaths per 1,000 patient years. The age specific number of RRT deaths is the actual number of deaths observed in 2016 in RRT patients. The RRT observed death rate was calculated as number of deaths observed in 2016 per 1,000 patient years exposed. Relative risk of death was calculated as the ratio of the observed and expected death rates for RRT patients. The death rate was calculated for the UK general population by age group and compared with the same age group for prevalent patients on RRT on 31 December 2015.
Methodology of cause of death
The EDTA-ERA Registry codes for cause of death were used. These have been grouped into the following categories:
Completeness of cause of death data was calculated for all prevalent patients on RRT that died in a specific year with cause of death data completed for that year. Patients that were lost to follow up or that recovered were not included in the cause of death completeness calculation.
Adult patients aged 18 years and over from England, Wales, Scotland and Northern Ireland were included in the analyses of cause of death. The incident patient analysis included all patients starting RRT in the years 2000-2015. Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 31 December 2015 and followed-up for one year in 2016.
Results

Incident (new RRT) patient survival Overall survival
The 2015 incident RRT cohort included 7,626 patients who started RRT. Survival at 90 days (adjusted to age 60) for the 2015 cohort was 96.5% and was similar compared to the previous year (96.8%) ( (table 5. 2). However, there are two important caveats for the interpretation of these data; the data have not been adjusted for differences in primary renal diagnosis, ethnicity, socio-economic status or comorbidity, which may differ by country. Secondly, there are known regional differences in the life expectancy of the general population within the UK (which may be explained by some of the factors outlined above). These general population differences are likely 
Survival by modality
It is not possible to make truly valid comparisons of survival of cohorts of patients starting different RRT modalities, as modality selection is not random. In the UK, the cohort of patients starting PD was younger and received a transplant more quickly than those starting HD. The age adjusted one year after 90 days survival estimates for incident patients starting RRT on HD and PD in 2015 were 88.3% and 92.5% respectively, with both HD and PD patient survival falling slightly from the previous year (figure 5.1) . This is the second year that the one year after 90 days survival on HD and PD has declined (figure 5.1).
Survival by age
Tables 5.4 and 5.5 show survival for the 2015 incident RRT cohort divided by age (565 years and ,65 years). Short term survival (at 90 days) was similar to the previous year for the younger age group, while it decreased for those 565 years compared with the 2014 cohort (97.8% to 97.7% for those aged 18-64 years and 93.2% to 92.2% for those 565 years respectively). There was a small decline in one year after 90 day survival for younger patients (,65 years) and an increase in survival for patients aged 565 years compared to the 2014 cohort (80.6% to 81.3%). There was a steep decline in survival with advancing age (figure 5.2).
There was a curvilinear increase in the death rate per 1,000 patient years with increasing age for the one year period from 90 days after RRT start ( figure 5.3) . The overall death rate in Wales was higher than in the other UK countries, mostly due to a higher death rate in Wales for patients 555 years old (figure 5.3) and a higher overall median age compared to the other UK countries. A similar finding is reported in table 5.12, where there was evidence that the one year death rate in prevalent dialysis patients (2015 cohort) was higher in Wales compared to England and Northern Ireland. This is also In patients over 85 years of age, the death rate was again lower in Scotland as was seen in the previous year, although the number of patients in this age group was relatively small (N = 31). Figure 5 .4 shows the long-term survival of incident patients from start of RRT (day 0), according to age at RRT start. More than 50% of patients who were aged between 45-54 years when starting RRT survived for over ten years. Median survival for those aged between 55-64 years at RRT start was around six years and median survival for those aged between 65-74 years was approximately 3.5 years. Figure 5 .5 illustrates the survival of incident patients, excluding those who died within the first 90 days and shows that the median survival of patients aged between 55-64 years was approximately 6.5 years and the median survival of patients aged between 65-74 years was approximately four years. These survival results are slightly better than survival from day 0 for the same age groups, as would be expected due to the higher mortality observed in the first 90 days of treatment.
Censoring at transplantation removes the fittest patients from the survival cohort and affects the appearance of the longer-term outcomes of the younger patients (who are most likely to have undergone transplantation). Without censoring, the ten year survival for patients aged 18-34 years was 83.8% (figure 5.4), however if survival is censored at transplantation this falls dramatically to 56.6% (data not shown). The ten year survival without and with censoring at transplantation were 70.7% and 43.9% for age group 35-44 years and 54.9% and 30.0% for age group 45-54 years respectively. This difference in survival becomes less pronounced with increasing age, especially for patients aged 65+. This was previously examined in more detail in the 2008 Annual Report [9] .
Age and the hazard of death Figure 5 .6 shows the monthly hazard of death from the first day of starting RRT by age group, which falls sharply during the first 4-5 months, particularly for older patients (565 years), after which time the hazard remained relatively stable up to one year.
The hazard of death at 90 days per ten year increase in patient age increased from 1.61 (2014 cohort) to 1.64 (2015 cohort) while the hazard in the first year after 90 days slightly decreased (1.59 in the 2014 cohort compared to 1.54 in the 2015 cohort) (table 5.6).
Survival by gender
There was no survival difference between genders in the incident RRT cohort of patients starting RRT from 2004 to 2013 and followed up for a minimum of three years until 2016 (figure 5.7). There was also no evidence of a survival difference between genders in the first 90 days and one year after the first 90 days (data not shown).
Survival in the 2006-2015 cohort
The death rate per 1,000 patient years in the first year of starting RRT from 2006 to 2015 is shown in figure 5 .8. Death rates were gradually increasing from 2013 onwards after a declining trend in the death rate over the past decade. It is important to note that these death rates Although survival improved overall between the 1998 and 2015 cohorts, the improvement was more pronounced in patients aged 565. There has been a 15.5% absolute improvement in one year survival from the 1998 to 2015 cohorts (table 5.8) versus 4.8% in those aged ,65 years during the same period. It is not possible to ascertain the specific reasons for this reduction in risk of death. not shown) and this is, at least in part, because younger and healthier patients are only included in the survival calculation up to the date of transplantation. In the oldest age group, the number of patients surviving beyond seven years was small, accounting for the variability seen.
Figures 5.13 and 5.14 show the same analysis for patients without diabetes and with diabetes respectively. An increased hazard of death over time is evident for patients with diabetes predominantly over 565 years of age.
Centre variability in one year after 90 days survival
Due to small numbers of incident patients in any given year in each centre and resultant wide confidence intervals, variability by renal centre was assessed in a larger cohort across several years. Similar to previous years, sustained performance was assessed in a rolling four year cohort from 2012 to 2015. These data are presented as a funnel plot in figure 5.15. Table 5 .9 allows centres to be identified on this graph by finding the number of patients treated by the centre and then looking up the corresponding number on the x-axis. Four centres (Wolverhampton, Cardiff, Swansea, Glasgow) had survival below the 95% lower limit whilst three centres (Gloucester, Reading, West Northern Ireland) had survival above the 95% upper limit and one centre (London West) above the 99% upper limit. This is compared with last year when three centres were survival outliers below the 95% lower limit and two centres above the 95% upper limit. With 71 centres included in the analysis it would be expected that three centres would be outside these limits by chance. It is important to highlight that these data have only been adjusted for age (i.e. no other patient factors such as comorbidity, primary renal disease or ethnicity) and have not been censored at transplantation. Therefore the effect of differing rates of transplantation by centre was not taken into account. Please see the following section for the effects of adjustment for primary renal disease and comorbidity. Appendix 1 of this chapter contains additional tables related to these survival analyses; Centre variability in one year after 90 day survival: impact of adjustment for comorbidity Although comorbidity returns to the UKRR have remained poor, some centres have consistently returned 585% comorbidity data for incident patients. The analyses in this section use a combined incident RRT cohort from 2012-2015 for the 29 centres who consistently returned comorbidity data for 585% of patients during this period and demonstrate the impact of sequential adjustment for age, primary renal diagnosis and comorbidity (table 5.10).
It can be seen that adjustment for age has the largest effect, most notably in those centres with the lower unadjusted survival figures. Survival improved for all centres after adjustment for age, as the average age of incident patients was over 60 years. There were only minor changes in survival for most centres after adjustment for primary renal diagnosis, but survival did increase by 50.8% for three centres (Shrewsbury, Swansea, York). In five centres (Newcastle, Swansea, Cardiff, Bradford, Clwyd) adjustment for comorbidity had a noticeable effect (51% increase) on adjusted survival (table 5.10, figure 5.16). After adjustment for age, primary renal diagnosis and comorbidity, Swansea, Antrim, Bangor and Clwyd had the largest improvement in survival of 8.3%, 8.0%, 6.5% and 6.1% respectively.
One of the largest survival improvements, as a result of adjustment for comorbidity was seen in Swansea. Adjustment for comorbidity may have an important differential effect for renal centres that have a higher comorbid burden in their RRT population. This could affect the status of centres as a survival outlier as shown in figure 5 .15, such as Swansea, Cardiff, Wolverhampton and Glasgow. However due to poor comorbidity returns for many renal centres, comorbidity adjustment for the entire incident RRT population is not yet possible. Data completeness and data quality both have significant implications for the accuracy of analyses such as these. Case-mix adjustment performed in a cohort of incident patients starting RRT in England from 2002 to 2006 which was linked to the Hospital Episodes Statistics (HES) data, found that three of the four survival outliers at that time were no longer outliers after adjustment for HES-derived case-mix. Case-mix adjusted survival for Wolverhampton was shown to increase substantially in this research. Swansea, Cardiff and Glasgow could not be evaluated in this research as this HES research only included English hospitals, but the study results highlight that observed variability in survival between centres is affected by case-mix [10] . High levels of deprivation such as in parts of Glasgow, Wales and some other areas have not been adjusted for and may impact on the mortality rate in these areas.
Survival in patients with diabetes
Patients with diabetes have been shown to have worse long term survival compared to patients without diabetes [3] . In the following analyses, 90 day survival, 1 year after 90 day survival and long term survival are presented according to the presence or absence of a diagnosis of diabetes as the primary renal disease.
In the UK in 2015, 90 day survival for incident patients with diabetes was better than those without diabetes across the age categories of 18-44 years, 45-64 years and 65 years and over (figure 5.17). For one year survival after 90 days in the 2015 cohort, young patients (18-44 years) without diabetes had better survival than their counterparts with diabetes, whereas for the 45-64 years group and those 65 years and over, the survival was more similar (figure 5.18).
Long term survival for patients with diabetes and patients without diabetes is presented for the incident RRT cohort of patients starting RRT from 2004 to 2013 with a minimum of three years follow up ( figure 5.19 ). These data show large differences between survival for those with diabetes and those without diabetes in the age groups 18-44 years and 45-64 years. In the age group 18-44 years, 89.7% of patients without diabetes were alive five years after start of RRT compared to 72.8% for patients with diabetes. In the age group 45-64 years, 69.9% of patients without diabetes were alive five years after start of RRT compared to 52.5% for patients with diabetes ( figure 5.19) . The initial survival difference where incident RRT patients without diabetes in the older age group (565 years) had poorer survival than incident patients with diabetes in the same age group, diminished over the years until there was very little difference in five year survival between these groups.
Survival in prevalent dialysis patients
Overall survival Table 5 .11 shows the one and two year survival for prevalent patients on dialysis. One year age adjusted survival for prevalent dialysis patients was essentially stable at 88.0% in the 2015 cohort compared to 88.3% in the 2014 cohort. Two year survival dropped slightly from 71.1% in the 2014 cohort to 69.9% in the 2015 cohort.
Survival by UK country
The one year death rate for prevalent dialysis patients in 2015 for each UK country is shown in table 5.12. The death rate rose in every UK nation compared to the 2014 cohort, except in Northern Ireland; the median age of prevalent dialysis patients remained similar in England and Wales, decreased slightly in Scotland and increased in Northern Ireland. The one year unadjusted death rate in Wales was significantly higher than in England and Northern Ireland. However, the higher median age in Wales and One year survival of prevalent dialysis patients by centre
The age adjusted (adjusted to age 60) one year survival of dialysis patients by centre is illustrated in a funnel plot (figure 5.20). As there are 70 centres included in the analyses, it would be expected that three centres would fall outside the 95% (1 in 20) confidence limits, entirely by chance. The survival for patients attending Salford was below the 95% confidence limit and there were no centres below the 99% confidence limit. Comparing data over a number of years, there was no centre that had consistently been below the 95% confidence limit. Five centres (Newry, Birmingham Queen Elizabeth Hospital, Aberdeen, London St Bartholomew's, London West) were above the 95% confidence limit and one centre (London St George's) was above the 99% confidence limit. A sensitivity analysis was performed without censoring at transplantation and the results for outlying centres were unchanged. These observed differences may have occurred by chance, may be true differences or may reflect differences in the case-mix of the renal centres. Transplantation listing practice (percentage of patients wait-listed within two years of RRT start, median time to wait-listing) and pre-emptive transplant rates in renal centres may have an impact on the survival results for prevalent dialysis patients. Table 5 .13 allows centres in figure 5 .20 to be identified by finding the number of patients treated by the centre and the corresponding survival and then looking this up on the axes of the funnel plot.
One year survival of prevalent dialysis patients by centre is illustrated in figures 5.21 and 5.22 for patients aged ,65 years and those aged 565 years.
Survival by age group Figure 5 .23 shows the one year survival of prevalent dialysis patients who were alive and receiving dialysis on 31 December 2015, stratified by age group. This demonstrates a curvilinear decrease in survival with increasing age.
One year death rate in prevalent dialysis patients by age group, 2015 cohort The death rates for prevalent patients on dialysis by age group are shown in figure 5.24. The younger patients included in this analysis are a selected higher risk group, as they remained on dialysis rather than undergoing transplantation. The increase in the death rate with age was not linear; in those aged ,45 years, a ten year 
Survival in prevalent dialysis patients with diabetes
In patients aged ,65 years, one year survival for prevalent dialysis patients with diabetes was approximately 8.0% lower compared to the same age group without diabetes. In contrast, for prevalent dialysis patients aged 65+ years, the survival difference was smaller between those with and without diabetes (2.5% lower, table 5.14). The relative risk of death on RRT decreased with age from a peak of approximately 25 times that of the general population at age 20-24 years to 1.5 times the general population at age 85 and over. Figure 5 .26 shows that the relative risk of death has decreased substantially for the younger age groups (,50 years) in recent years, whereas the relative risk of death in patients aged over 50 has not changed greatly in the 2015 cohort compared to the 1998-2001 cohort. The overall relative risk of death was 5.6 in the 2015 cohort and was slightly lower compared to the previous year (relative risk of death 6.1).
Cause of death Data completeness
Overall completeness of data for cause of death in the UK was similar to the previous year: 63.5% in 2015 and 63.2% in 2016. Cause of death data completeness declined in England and Northern Ireland by −1.7% and −0.8% respectively but increased by 9.4% and 5.3% in Scotland and Wales respectively (appendix 1: Survival tables, table 5.27). There was substantial variability in the completeness of cause of death data between centres, with 
Cause of death in incident RRT patients
The number and proportion of patients in the cohort with missing data for cause of death is shown in the last row of each cause of death table (tables 5.17 to 5.21).
Cause of death within the first 90 days
In the first 90 days after start of RRT, cardiac disease was the most common cause of death in both age groups. Infection and treatment withdrawal as a cause of death were more common in older patients (aged 65+), whereas malignancy was more common in younger patients (,65 years old) (table 5.17).
Cause of death within one year after 90 days
In the year after the first 90 days, treatment withdrawal as a cause of death was more common in older patients (aged 65+), whereas cardiac disease was more common in younger patients (,65 years old) (table 5.18). Although cardiac disease remained the leading cause of death in both older and younger age groups at one year after the first 90 days, it has decreased over time.
Cause of death in prevalent RRT patients in the 2015 cohort Table 5 .19 shows the comparison of cause of death for prevalent dialysis and transplant patients in the 2015 cohort. Cardiac disease as a cause of death was less common in patients with a transplant who were a highly selected group of patients. Malignancy was responsible for a far greater percentage of deaths in prevalent patients with a transplant than in those receiving dialysis; infection was also more common. Treatment withdrawal was a more common cause of death in the prevalent dialysis population. Table 5 .20 shows the cause of death for prevalent dialysis patients in the 2015 cohort, divided into subgroups according to age. Again, cardiac disease was the leading cause of death overall. Cardiac disease represented a higher proportion of all deaths (amongst those where cause of death was known) in younger (,65 years) dialysis patients, although the absolute number of cardiac deaths were higher amongst those Cardiac disease  847  26  195  27  652  25  Cerebrovascular disease  146  4  30  4  116  4  Infection  597  18  112  15  485  19  Malignancy  313  9  100  14  213  8  Treatment withdrawal  538  16  77  11  461  18  Other  727  22  181  25  546  21  Uncertain  140  4  29  4 Cardiac disease  807  24  698  24  109  19  Cerebrovascular disease  159  5  129  5  30  5  Infection  696  20  570  20  126  22  Malignancy  351  10  218  8  133  23  Treatment withdrawal  565  17  544  19  21  4  Other  659  19  548  19  111  20  Uncertain  181  5  145  5  36  6  Total  3, aged 565 years (34% versus 21%). Prevalent dialysis patients aged 565 years were substantially more likely to withdraw from treatment than younger patients (22% and 10% respectively). Table 5 .21 shows the cause of death for prevalent transplant patients in the 2015 cohort, divided into subgroups according to age. It shows that cardiac disease was more common in the younger age group (similar to that seen for dialysis patients, table 5.20), whereas infection was much more common in older transplant patients. The proportions of other causes of death were relatively similar between older and younger patients. 
Cause of death
N % N % N %111 4 Total 3,308 724 2,584 Missing data 2,873 46 642 47 2,231 46
Discussion
Survival of incident patients on RRT at 90 days (adjusted to age 60) was slightly lower compared to the preceding year. When analysed according to age group, 90 day survival declined for those 565 years whilst it was similar for the younger patients. Incident one year after 90 days survival (adjusted to age 60) declined slightly in the 2015 cohort compared to 2014, due to decreased survival in patients aged ,65 years of age. There was no difference in survival by gender. Long term survival of incident patients on RRT continued to improve gradually over time.
There were differences in short term incident survival (90 days and one year after 90 days) by combined age group and diagnosis of diabetes; 90 day survival was better for those with diabetes across all age groups. For survival one year after 90 days, in the younger age group (,65 years) survival was much better for those patients without diabetes, however, this association was Cardiac disease  698  24  251  34  447  21  Cerebrovascular disease  129  5  35  5  94  4  Infection  570  20  148  20  422  20  Malignancy  218  8  57  8  161  8  Treatment withdrawal  544  19  71  10  473  22  Other  548  19  139  19  409  19  Uncertain  145  5  43  6  102  5  Total  2,852  744  2,108 No cause of death data 1,464 34 395 35 1,069 34 not seen in the older age group (565 years), where survival was more similar between patients with and without diabetes. Long-term survival showed a similar picture, where younger (,65 years) patients without diabetes survived much better than similar aged patients with diabetes. Survival was similar for older patients (565 years) with and without diabetes. One year age adjusted survival for prevalent dialysis patients was approximately the same in 2015 compared to 2014 (88.0% and 88.3% respectively). Prevalent dialysis patient survival in the UK seems to have peaked in 2011 and has been slightly lower in more recent years. The age adjusted one year survival for prevalent dialysis patients with diabetic primary renal disease in the UK has decreased slightly from 2011 onwards. The relative one year risk of death on RRT at age 20-24 years is 25 times that of the same age group in the general population, but has improved markedly over time (compared with a relative risk of 41 in the 1998-2001 cohort of the same age). For older patients (70-74 years) the relative risk is lower at 7.8 compared with the general population of a similar age, but this relative risk has not improved over time.
In the prevalent dialysis population for whom data regarding cause of death were available, cardiovascular disease was the most common cause of death accounting for 24% of deaths. Infection accounted for 20% of deaths and treatment withdrawal for 19% of deaths, with differences seen according to age group. In contrast, malignancy was the most common cause of death in prevalent transplant patients (23%), whilst infection accounted for 22% and cardiac disease 19% of all deaths. Trends in cause of death over time (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) show a decrease in cardiovascular disease, an increase in treatment withdrawal from 2009 onwards and a plateauing of deaths related to infection.
Variability in survival between centres was still evident, with some centres appearing as outliers in the data (below the lower 95% and above the upper 95% confidence limits) in incident RRT and prevalent dialysis patient survival. The survival analyses in this chapter have not been adjusted for any case-mix factors except for age. Differences in proportions of primary renal diagnosis, ethnicity and comorbidity have not been considered due to missing data from some renal centres. Although research has suggested that adjustment for comorbidity only explains a modest part of the variance in ERF patient outcomes [11] , the prevalence of comorbidities could vary substantially between renal centres and it would be expected that adjustment for comorbidity may explain a proportion of the variance in survival. The UK Renal Registry regularly evaluates the effect of adjusting for primary renal diagnosis and comorbidity in addition to age in those centres returning 585% of comorbidity data and repeatedly shows that, at centre level, there is clear benefit for some centres in adjusting for these case-mix factors. Research using comorbid conditions identified from Hospital Episode Statistics (HES) data for RRT patients in England during 2002 England during -2006 showed that adjustment for HES-derived case-mix, including comorbid conditions, affected the position on the funnel plot and outlying status of some renal centres for incident patients and reduced outlying centres from four to one [10] . Routine linkage of the UK Renal Registry data with hospital admissions information in the UK will allow the UKRR to report on survival adjusted for case-mix (age, ethnicity, primary renal diagnosis and comorbidity) in future UKRR reports. This will provide an improved comparison between centres and more accurate identification and location of outlying centres on funnel plots. There was also considerable centre level variability in the early hazard of death (e.g. first six months) from start of RRT. The proportion of deaths in the first 90 days of starting RRT varied at centre level and in some centres the proportion was very low or even zero (data not shown). This may be due to unreported deaths in patients that die within the first 90 days of starting RRT for ERF. Alternatively, it may be due to those patients being described as having acute kidney injury (AKI) and therefore not included in the historical UKRR data collection. From January 2015, the UKRR began collecting data for patients receiving RRT for acute dialysis in renal centres in England and some Welsh centres, therefore future survival analyses will be able to take account of these discrepancies.
There is recognised variability in how conservative care is delivered and this is likely to contribute to centre differences in the population who start dialysis, particularly amongst older patients [12] . Historically, the UKRR has been unable to collect data on patients opting for conservative care rather than RRT for their chronic kidney disease. From January 2016 the UKRR began collecting data for patients with chronic kidney disease (CKD) stage 4 and 5 seen in renal centres in England, Wales and Northern Ireland. This will further improve understanding of case-mix differences between centres as well as understanding centre differences in the transition from CKD to RRT or conservative care and how this may impact on survival. In the future, patient frailty data, which has been shown to be independently associated with the timing of RRT start as well as outcomes may further augment the analysis [13] .
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